Madeleine Johnson

The FDA thus far has not been interested in PCR tests to identify specific SARS-CoV-2 variants, but that may be changing with the emergence of Omicron.

The Association of Public Health Laboratories is directing member labs to focus sequencing efforts on S-gene dropouts for the next week.

With new financing from Koch Disruptive Technologies and guidance from industry experts, the firm expects to launch its system next year.

The firm outlined the ways it continues to diversify its core business while expanding both its headcount and footprint.

The firm strengthened its Cor this week by announcing two new assays for the high-throughput, automated system.

At the ASHG meeting, early-access users compared the newly launched Naica Prism 6 to next-generation sequencing, qPCR, and other digital PCR instruments.

The system incorporates robotics from Hamilton and thermal cycling from Bio-Rad Laboratories, and is scheduled to launch early next year.

Thermo Fisher plans to expand its footprint in digital PCR, beginning with the tools space and ultimately reaching into applied markets.

As the pandemic continues to play out, test developers aren't sure how it will impact STIs and their work around developing and manufacturing tests.

Seattle-based ID Genomics is partnering with a diagnostics instrument developer to adapt its genetic fingerprinting methods for point-of-care use.